局部晚期宫颈癌推量治疗:近距离放疗与MR-Linac的剂量学比较
结果显示MRL在部分情况下可达到既定计划约束,但所有MRL计划的直肠D2cm3更高,BT仍是首选推量方式。
要点
- MRL推量在部分患者中可达到EMBRACE II计划约束,但直肠剂量普遍更高。
- BT在高剂量区体积更大,MRL在低剂量区体积更大,剂量分布根本不同。
- BT的CTVHR至直肠、乙状结肠、肠道表面距离更大,BT仍为首选推量方式。
核心结论
- MRL推量计划在部分情况下可达到既定计划约束,但直肠剂量更高且剂量分布与BT根本不同,BT仍是首选推量方式。
- MRL剂量分布对肿瘤学结局的影响需临床试验进一步研究。
研究设计与样本
- 回顾性研究,个体内比较BT与MRL推量计划的剂量学差异。
- MRL计划基于未放置施源器的MRI扫描制定,比较DVH参数、靶区至危及器官表面距离及适形度比值。
主要发现
- 组1中MRL与BT的处方靶区剂量水平相似,组2中BT的所有处方靶区剂量水平显著更高。
- 所有MRL治疗计划的直肠D2cm3均更高。
- BT的高剂量水平体积更大,MRL的低剂量水平体积更大。
- BT的CTVHR至危及器官(直肠、乙状结肠、肠道)表面距离更大。
关键数值与推荐
- 组1为BT时至少一项EMBRACE II计划约束未达到,组2为全部计划约束达到。
- 所有MRL计划的直肠D2cm3均高于BT计划。
临床怎么用
- BT仍应作为局部晚期宫颈癌推量治疗的首选方式。
- MRL推量可作为BT不可行时的备选,但需关注直肠剂量升高。
局限性
- 回顾性研究设计。
- MRL计划基于未放置施源器的MRI扫描制定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Standard treatment for locally advanced cervical cancer (LACC) is chemoradiotherapy followed by a brachytherapy (BT) boost. However, BT is not always feasible and magnetic resonance (MR)-guided adaptive radiotherapy on the MR-Linac (MRL) might be an alternative. To investigate the dosimetric feasibility of MRL, BT and MRL treatment plans were compared intra-patient in terms of dosimetric differences, next to anatomical and conformity variations. MATERIALS AND METHODS: Two groups of ten patients with LACC treated with BT boost were selected: group 1 included patients for which at least one clinically established (EMBRACE II) treatment planning constraint was not achieved during BT, in group 2 all planning constraints were achieved.BT treatment plans were compared with MRL treatment plans (based on MRI scans without applicator in place) intra-patient, in terms of dose-volume histogram (DVH) parameters, target-to-OAR (organ at risk) surface distances and conformity ratios. RESULTS: Group 1 resulted in similar prescribed target dose levels for MRL compared to BT, for group 2 all prescribed target dose levels were significantly higher for BT. Rectum D2cm3 was higher for all MRL treatment plans. Volumes of higher dose levels were larger for BT, volumes of lower dose levels were larger for MRL and the CTVHR to OAR (rectum, sigmoid, bowel) surface distance was greater for BT. CONCLUSION: This retrospective study demonstrates that with an MRL boost plan, in some situations it is possible to achieve established planning constraints. However, as rectum doses are higher and dose distributions are fundamentally different, BT remains the modality of choice. Clinical trials are necessary to investigate the influence of the MRL dose distribution on oncological outcomes.
引用
- van Noortwijk R, Kroon PS, van Vliet-van den Ende KM, et al. Dosimetric comparison between brachytherapy and MR-Linac as a boost modality for locally advanced cervical cancer. Clin Transl Radiat Oncol. 2025. PMID: 41537166. doi:10.1016/j.ctro.2025.101098
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。